ArticleInternational journal of clinical oncology2025
Risk factors for second primary cancers in patients with curatively resected gastric cancer.
Article in International journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Receptor status, molecular subtypes, and survival outcomes of breast cancer following gastric cancer compared with single primary breast cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeDespite improving long-term outcomes after gastrectomy for gastric cancer (GC), screening methods for second primary cancer (SPC) following resection remain challenging. This study aimed to investigate the cumulative incidence and risk factors for SPC in patients with curative resection for GC.
methodsWe included 1128 patients who underwent R0 resection for Stage I/II/III GC. Incidence of duplicate cancers before and after gastrectomy was investigated. The cumulative incidence of SPC following gastrectomy was calculated, and the relationship between SPC occurrence and clinicopathological factors was analyzed.
resultsDuring a median postoperative follow-up of 64 months, the most common SPCs were lung, prostate, and colorectal cancers. Additionally, lung and pancreatic cancers occurred significantly more frequently after gastrectomy than before. The cumulative incidence of SPCs was 7% at 5 years, 18% at 10 years, and 29% at 15 years. Multivariate analysis identified male sex, postoperative carcinoembryonic antigen (CEA) levels ≥ 5.0 ng/mL, and albumin levels ≤ 3.8 g/dL at one month after gastrectomy as significant factors associated with SPC development.
conclusionAfter gastrectomy for gastric cancer (GC), enhanced surveillance for SPCs can be tailored based on three factors: male sex, postoperative CEA levels ≥ 5.0 ng/mL, and albumin levels ≤ 3.8 g/dL.
Indexed as
Identifiers
40783632What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.